PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1146001
PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1146001
The desalting and buffer exchange market is projected to register a CAGR of 10% during the forecast period (2022-2027).
The sudden outbreak of COVID-19 and the rise in the number of COVID-19 infection cases across the world have increased the demand for vaccination and drugs. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), in 2021, 11 billion COVID-19 vaccines were produced, and nearly 200 vaccine candidates were in the production pipeline. The desalting and buffer exchange products have been extensively used in the vaccine production process as the buffer exchange is an important step in the downstream process. Hence, COVID-19 had a positive impact on the desalting and buffer exchange market due to the high demand for effective COVID-19 vaccination worldwide.
Furthermore, increasing demand for biopharmaceutical products coupled with the rise in research and development expenditure on biopharmaceutical products is expected to drive the market's growth. This is mainly due to the crucial role of desalting and buffer exchange in the downstream production process of the drugs. According to a report published in 2021 by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), biopharmaceutical research and expenditure in 2020 totaled more than USD 189 billion globally. Therefore, the increasing expenditure on the research and development of biopharmaceuticals is expected to boost the market's growth as they extensively use desalting and buffer exchange systems in the manufacturing process.
Additionally, the increasing investment by the market players in the research and development of products and facilities supporting them is also expected to propel the growth of the market. For instance, in April 2022, Thermo Fisher Scientific opened its new single-use technology manufacturing site in Ogden, Utah, the United States. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The facility will manufacture highly customizable bioprocess container (BPC) systems. The USD 44 million facility is part of Thermo Fisher's USD 650 million multi-year investment to help ensure flexible, scalable, and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19. Hence, such investments by the market players are expected to drive the demand for purification processes of the final products, thereby boosting the growth of the market.
Thus, owing to the abovementioned factors, the market is expected to show significant growth over the forecast period. However, a lack of skilled professionals may impede the growth of the market.
During COVID-19, there was a rapid increase in the market for desalting and buffer exchange products. This was primarily due to increased demand for biopharmaceutical drugs, effective therapies, and increased R&D in the pharmaceutical and biotechnology industries during the pandemic era.
The increase in research and developmental activities in the pharmaceutical and biotechnology industries in order to manufacture biopharmaceutical products will increase the demand for desalting and buffer exchange systems. For instance, as per the January 2021 update by the United States Food and Drug Administration, in 2020, 53 novel therapeutics were approved by the Food and Drug Administration (FDA). Since desalting and buffer exchange is based on separating macromolecules from relatively smaller molecules, which play a crucial role in downstream applications of several final products, the growth in novel drug development by pharmaceutical and biotechnology companies will drive the growth of the segment.
Moreover, according to data published by the Organisation for Economic Cooperation and Development (OECD) in 2020, the pharmaceutical industry in OECD countries spent nearly USD 101 billion on research and development. The same source also reported that global R&D spending by the largest publicly traded companies grew 13.7% annually.
Therefore, the increasing expenditure on research and development by the biopharmaceutical and biotechnology industries to develop their product pipeline is expected to boost the growth of the segment over the analysis period.
North America is anticipated to hold a major share in the desalting and buffer exchange market. Increasing demand for biopharmaceuticals and rising research and development expenditure for biopharmaceutical companies are the contributing factors to the market growth in this region.
According to the Organisation for Economic Co-operation and Development (OECD), in 2020, the United States recorded USD 0.61 million in research and development expenditure in the biopharmaceutical industry. Thus, the increasing research and development expenditure in the pharmaceutical industry is a major factor that propels the growth of the market in this region.
Additionally, the increasing focus by the market players on the research and development of cell biology products is also expected to propel the growth of the market. For instance, in July 2022, Cytiva planned to spend USD 1.5 billion to build its first chromatography resin plant outside Sweden. The company acquired a facility in Muskegon, Michigan, where the resin will be produced, which can be used to purify and analyze biomolecules. Cytiva will get support from the State of Michigan and several United States agencies, including the Biomedical Advanced Research and Development Authority. Such investment by the market players and support from the public authorities is also contributing to the growth of the market.
Therefore, the increasing expenditure on research and development by the biopharmaceutical and biotechnology industries to develop their product pipeline is expected to boost the growth of the desalting and buffer exchange market, thereby collectively contributing to the market growth in the North American region.
The desalting and buffer exchange market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are ThermoFisher Scientific, Sartorius AG, Merck KGaA, Agilient Technologies Inc., Repligen, PhyNexus, Inc, Biogen, Norgen Biotec Corp., Danaher, and others.